New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKsNew data confirm durable clinical benefit across multiple higher-order response measures, including CDAI LDA and DAS28 LDA, after Week 28 for at least three months off drugUpdated safety data through Week 38 demonstrate rosnilimab was well-tolerated with no treatment-related serious adverse ev ...